Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2016-10-31 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at a conference (BIO-Europe 2016). Form 6-K filings are periodic reports for foreign private issuers to disclose material information. The document is short (1875 characters) and primarily serves as a regulatory filing to announce the press release. It does not contain detailed financial statements or comprehensive report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full report or presentation.
2016-10-31 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release about a patent allowance in Japan for a drug candidate. The document is short (1911 characters) and primarily serves as a regulatory announcement of a press release rather than a detailed financial report or other specific filing. It does not contain financial statements, management discussion, or detailed report content. According to the rules, such filings that are announcements or press releases submitted on Form 6-K are best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2016-10-18 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at the BIO Investor Forum 2016. The document is short (1872 characters) and primarily serves as an announcement of the press release rather than containing detailed financial data or a full report. Form 6-K filings are typically used for current reports by foreign private issuers and often include announcements or updates rather than full annual or quarterly reports. Given the length and content, this is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a Management Report or Investor Presentation itself but an announcement of a presentation. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and filings that do not fit other categories.
2016-10-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a webcast following an announcement of progress on a clinical program. The document is short (2029 characters) and primarily serves as a regulatory filing to report current events or updates by the company. It does not contain detailed financial statements, management discussion, or comprehensive report data. Form 6-K filings are typically periodic reports for foreign issuers to disclose material information between annual reports. Given the nature and length of the document, it fits best under Regulatory Filings (RNS) as a general update and press release filing rather than a full report or earnings release.
2016-10-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a progress update on a clinical trial program (RHB-104 Phase III Crohn's Disease Program) and mentions an option for early stop for success. The document is short (1957 characters) and primarily serves as a regulatory update with an attached press release. It does not contain detailed financial statements, comprehensive management discussion, or full report content. According to the rules, Form 6-K filings are periodic reports for foreign private issuers that provide updates but are not full annual or interim reports. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2016-10-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release announcing the initiation of a Phase II study for a drug, which is a typical content for a Form 6-K. The document is short (1952 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor an earnings release or management discussion. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified under Regulatory Filings (RNS). Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-10-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.